The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy-Reference-Cited by-全球学者库

The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy

Published:2022-09-17 Issue:1 Volume:11 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Huang Jiwei¹,Su Ruopeng¹,Chen Zeyu²,Jiang Shuai³,Chen Minfeng⁴,Yuan Yichu⁵,Hu Hailong⁶,Fu Changde⁷,Huang Zhiyang⁷,Wang Zhenyu⁸,Zheng Bing⁸,Li Chancan⁹,Wang Zaoyu¹⁰,Bao Yige²,Cai Ming⁵,Guo Jianming³,Wei Qiang²,Xue Wei¹

Affiliation:

1. Department of Urology, Ren Ji Hospitlal, Shanghai Jiao Tong University School of Medicine, Shanghai, China

2. Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China

3. Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China

4. Department of Urology, Xiangya Hospital, Central South University, Changsha, China

5. Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

6. Department of Urology, The second hospital of Tianjin medical university, Tianjin, China

7. Department of Urology, Quanzhou First Hospital affiliated to Fujian Medical University, Quanzhou, China

8. The Department of Urology, The Second Affiliated Hospital of Nantong University, Nantong, China

9. The Department of Urology, AnHui NO. 2 Provincial People Hospital, Hefei, China

10. Department of Pathology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Funder

Basic Oncology Research Program from Bethune Charitable Foundation

Incubating Program for Clinical Research and Innovation of Renji Hospital

Shanghai Science and Technology Commission Research Project

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2022.2124691

Reference35 articles.

1. Cancer Statistics, 2021

2. Prognostic Factors in Upper Urinary Tract Urothelial Carcinomas: A Comprehensive Review of the Current Literature

4. An Analysis of Staging and Treatment Trends for Upper Tract Urothelial Carcinoma in the National Cancer Database

5. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A sialyltransferases-related gene signature serves as a potential predictor of prognosis and therapeutic response for bladder cancer;European Journal of Medical Research;2023-11-15

2. A metachronous bilateral upper urinary tract urothelial carcinoma achieved partial remission by multiple treatment modalities: A case report and literature review;2023-11-14

3. Clinical outcomes of immune checkpoint inhibitor plus nab-paclitaxel in metastatic upper tract urothelial carcinoma;Translational Andrology and Urology;2023-09

4. Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real‐world study;Cancer Medicine;2023-03-23

5. The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer;Frontiers in Immunology;2023-03-07